<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635401</url>
  </required_header>
  <id_info>
    <org_study_id>A3051043</org_study_id>
    <nct_id>NCT00635401</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking</brief_title>
  <official_title>A Multicenter, Open-Label Study Exploring the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of varenicline in Japanese
      smokers. Efficacy is evaluated by continuous quit rate and withdrawal symptoms of smokers.
      Safety is evaluated by adverse events, laboratory tests, and other safety tests.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carbon monoxide (CO)-confirmed 4-week continuous quit rate (4-week CQR) from Weeks 4 to 7.</measure>
    <time_frame>Weeks 4-7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CO-confirmed 7-day Point Prevalence from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous abstinence rate from target quit date (TQD) from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of daily cigarettes smoked from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of withdrawal symptoms by Minnesota Nicotine Withdrawal Scales (MNWS) from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of satisfaction (desirable and aversive effects) obtained from smoking by Smoking Effects Inventory (SEI) (administered only to subjects who had smoked since the previous assessment) from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tobacco craving by the Brief Questionnaire of Smoking Urges (QSU-Brief) from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effect of smoking cessation on subjects' quality of life by the Smoking Cessation Quality of Life (SCQoL) questionnaire from Week 2 through Week 7.</measure>
    <time_frame>Weeks 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, laboratory test changes throughout the study.</measure>
    <time_frame>Weeks 1-7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>0.5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>0.5 mg BID for 7 weeks</description>
    <arm_group_label>0.5 mg BID</arm_group_label>
    <other_name>Chantix, Champix, CP-526,555</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese smokers motivated to quit smoking

          -  No period without smoking of more than 3 months

          -  Smoked an average of at least 10 cigarettes/day in the past year

        Exclusion Criteria:

          -  Subjects who have used nicotine replacement therapy within 1 month of the study
             screening visit

          -  Subjects intending to use nicotine replacement therapy or other smoking cessation
             treatments during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuo-ku Fukuoka</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishi-ku Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3051043&amp;StudyName=A%20study%20of%20the%20efficacy%20and%20safety%20of%20varenicline%20in%20Japanese%20smokers%20motivated%20to%20quit%20smoking</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

